Liver maintains a unique tremendous regeneration capacity in response to partial hepatectomy (PH) or injury. Hepatocyte proliferation critically contributes to the process of liver regeneration (LR), which is regulated by various cytokines and growth factors. However, the molecular basis of LR remains unclear. Emerging evidence indicates that microRNAs (miRNAs, miRs) are involved in controlling hepatocyte proliferation during LR. In this review, an overview is provided to cover recent achievements in studies on the roles of miRNAs in LR. Studies on the regulatory effects of miRNAs and associated molecular mechanisms in LR will help enhance the understanding of the regenerative process and open up a new prospect for liver transplantation.

Currently, the most classical model of liver regeneration (LR) is established by Higgins and Anderson through a two-thirds hepatectomy on rodents [1]. The liver restores its original weight within two weeks following partial hepatectomy (PH) [2,3,4,5]. LR is a continuous pathophysiological process with a sequence of distinct phases, including an initiation phase, a proliferation phase, and a termination phase [2,6]. In the initiation phase, hepatocytes are in a state of reproduction capacity [2,6]. In the proliferation phase, cell population is growing up [2,6]. In the termination phase, regeneration is terminated through an apoptosis-proliferation balance [2,6]. Most normal hepatocytes remain in a relatively dormant state in the baseline. After PH, numerous hepatocytes enter G1 phase from G₀ phase of the cell division cycle, indicating a proliferative activity. In recent years, a well-orchestrated interplay of cytokines, growth factors and signaling pathways has emerged as important regulators in the process of priming and proliferation phases of LR, including tumor necrosis factor (TNF), interlukin-6 (IL-6), hepatocyte growth factor (HGF), epidermal growth factor (EGF), and transforming growth factor-α (TGF-α) [7,8,9,10,11,12,13,14]. Once the liver restores to its original mass, LR enters the termination stage which is controlled by a group of growth inhibitors, such as activin A and TGF-β [15,16,17,18,19,20,21].

Recently, increasing evidence has indicated roles of microRNAs (miRNAs, miRs) in regulating proliferation of hepatocytes [22]. MiRNAs are a class of small non-coding RNAs post-transcriptionally regulating gene expressions through combining to the 3' UTR of their target gene messenger RNAs (mRNAs), which leads to mRNA degradation and/or translation inhibition. MiRNAs participate in many important biological processes including cell growth, proliferation, differentiation, apoptosis and metabolism [23,24,25]. Dysregulated miRNAs have been reported to be involved in a spectrum of liver diseases [26,27,28,29,30,31,32]. Interestingly, circulating miRNAs have emerged as promising biomarkers for the diagnosis and prognosis of liver disease, cancers or many other diseases [22,33,34]. Growing evidence has indicated that miRNAs play roles in LR via either accelerating or inhibiting the proliferation of hepatocytes. This review covers recent advances in regulatory effects of miRNAs and potential mechanisms in LR.

In previous studies, miRNA profiles in livers of rodents receiving PH were analyzed. In a murine model of 50% PH, most miRNAs, including miR-16, miR-22, miR-23, miR-24, miR-29, miR-30, miR-122a, miR-126, and miR-145 were decreased during the process of LR, while some miRNAs, including miR-21, miR-26b, miR-192 and miR-194, were increased in the first day and then decreased in the following two days during the process of LR [35].

Besides that, 70% PH was the most used experimental murine model which helps elucidate the mechanisms underlying LR, where some miRNAs, including miR-26a, miR-33, miR-127, miR-150 and miR-378, were decreased [36,37,38,39,40], while some other miRNAs, including miR-34a, miR-122, miR-203 and miR-221, were increased during the process of LR [41,42,43,44,45] (Table 1). Interestingly, certain miRNAs, including miR-21, could be further altered during liver regeneration in response to chronic ethanol feeding; the latter inhibits and delays liver regeneration in experimental animal models [46,47]. To confirm potential target genes of these abnormally expressed miRNAs, the upregulation of cyclins (A, D, E, F, and G), cyclin-dependent kinases (CDKs) and E2F transcription factors that function as regulators for cell cycle and proliferation was also identified [48,49,50,51]. However, further studies are highly needed to clarify the direct association between these miRNAs and LR.

In another study performed by Shu et al. [52], a biphasic expression pattern of miRNA in livers post PH has been detected. It was characterized by an upregulation of ∼40% of the miRNAs tested at 3-18 hrs post PH, which was followed by a downregulation of ∼70% of the miRNAs tested at 24 hrs post PH. Specially, biphasic expressions of let-7, miR-21, miR-29 and miR-30 were further confirmed using qRT-PCRs. These miRNAs were firstly increased (3 hrs post PH) and then decreased (24 hr post PH) in livers. Intriguingly, the overexpression of these miRNAs at the priming stage of LR triggers the downregulation of miRNA-processing genes, including Rnasen, Dgcr8, Dicer, Tarbp2 and Prkra, which in turn results in the downregulation of miRNAs in the subsequent stage of LR to allow the liver to regenerate via a negative feedback mechanisms [38,52,53,54].

In addition, several studies have confirmed that miRNA profiles were associated with three discrete cellular polysome populations, including free and cytoskeleton- and membrane-bound ones in both quiescent and regenerating rat liver [55,56,57]. As LR progresses, several miRNAs change their polysome distribution pattern which is likely to follow the changes of their target mRNAs. Therefore, the interplay between polysomes and miRNAs may be involved in the regulation of posttranscriptional gene expressions.

MiR-21 accelerates hepatocyte proliferation

In Song et al.'s study, an animal model was established by inactivating the DiGeorge syndrome critical region gene 8 (DGCR8), which resulted in miRNA deficience [38]. Intriguingly, a delay in cell cycle progression from G1 to S phase was detected in this animal model, which proved the role of miRNAs in controlling cell growth and proliferation. The miRNA expression was analyzed during the early stage of LR post PH in wild-type mice. The results showed a strong induction of miR-21 at 18 hr post PH. Moreover, B-cell translocation gene 2 (Btg2), a cell cycle inhibitor, was confirmed as a direct target gene of miR-21 [58,59,60]. Btg2 could suppress the activation of fork-head boxM1 (FoxM1), an essential protein for DNA synthesis in hepatocytes post PH [38]. Therefore, hepatocyte proliferation could be accelerated through the inhibitory effect of miR-21 on Btg2.

To investigate how miR-21 stimulates LR, Ng et al. established a rodent model incapable of inducing miR-21 expression in hepatocytes using a miR-21 antisense oligonucleotide (miR-21-ASO), which led to complete elimination of miR-21 surge induced by PH in hepatocytes [61]. Immunostaining and Western blotting analysis demonstrated that cyclin D1 was induced at 18 hr after PH in livers of control mice while mice injected by miR-21-ASO 6 hr after PH displayed attenuated induction of cyclin D1. These data indicate that miR-21 is responsible for cyclin D1 induction and subsequent G1 phase transition of hepatocytes following PH. In addition, gene ontology analysis was carried out to determine the mechanisms how miR-21 induces cyclin D1 expression. Among the candidate genes, the mRNA and protein levels of Rhob, a well-known GTPase as a suppressor of cancer cell growth, transformation, and metastasis, were found to be negatively correlated with the expression of miR-21 induced by PH. Moreover, Rhob mRNA and protein levels were increased in livers of mice treated with miR-21-ASO injection. Based on the results from bioinformatics and luciferase assays, the inverse correlation between miR-21 and Rhob was further clarified. Viewed together, Rhob is directly inhibited by the miR-21 surge induced by PH during the early phase of LR. More importantly, the activation of Akt1 and mammalian target of rapamycin complex-1 (mTORC1) following Rhob inhibition is confirmed, which is responsible for mediating the positive effect of miR-21 on cyclin D1 translation and enhanced liver regenerative capacity post PH.

A recent study from Yan et al. demonstrated that the expression of miR-21 began to decrease immediately after the transition of most hepatocytes from G1 to S phase, suggesting that miR-21 may promote cell cycle progression before the entry into S phase [62]. Flow cytometry analysis showed that the proportion of S-stage hepatocytes was significantly increased or decreased by miR-21 mimics or inhibitors, respectively, indicating that miR-21 promotes cell cycle progression via accelerating the transition of hepatocytes to S phase. Furthermore, it has been reported that miR-21 negatively regulated PTEN at post-transcriptional level in cultured hepatocytes. As the PI3K/Akt signaling pathway is negatively regulated by PTEN, they further confirmed that the activation of PI3K/Akt signaling pathway due to PTEN inhibition is responsible for the promoting effect of miR-21 on LR.

Interestingly, it has also been reported that ursodeoxycholic acid (UDCA), a strong inducer of miR-21, could further upregulate miR-21 expression in LR post PH, which might provide novel approaches to improve the regenerative capacity of liver [63].

MiR-23b suppresses TGF-β1-induced apoptosis in hepatocytes by Smad3 inhibition

The TGF-β is an essential regulator involved in the cessation of liver growth once liver is regenerated to normal mass [20,21]. A previous study has demonstrated that miR-23b could downregulate the TGF-β/bone morphogenetic protein (BMP) signaling by inhibiting Smads [64,65,66]. In fact, it has been shown that miR-23b was notably reduced at the termination stage of LR (120 hr after PH) [67]. Moreover, miR-23b mimics promoted while miR-23b inhibitor prevented the proliferation and cell cycle progression of BRL-3A cells in vitro. Smad3, one downstream protein of TGF-β1 signaling, was markedly down regulated in miR-23b overexpressing cells. Luciferase assays further confirmed Smad3 as a direct target gene of miR-23b. In addition, flow cytometry showed that up-regulation of miR-23b could suppress TGF-β1-induced apoptosis in BRL-3A cells via inhibition of Smad3 expression. Intriguingly, TGF-β1 has been shown to inhibit miR-23b expression at the transcriptional level. Thus, the TGF-β1/miR-23b/smad3 signaling is supposed to be a novel mechanism in the termination stage of LR.

MiR-122, a miRNA biomarker of acute liver failure patients with spontaneous recovery

LR is involved in the spontaneous recovery process of a portion of patients suffered from acute liver failure (ALF) [68,69]. A study was conducted by John et al. to clarify the association between miRNA and spontaneous LR in ALF patients [42]. A notable increase in miR-122 level was detected in both serum and liver tissues of spontaneously recovered patients as compared to nonrecovered patients. Previously, heme oxygenase-1 (HO-1) was confirmed as a target gene of miR-122 with inhibitory effects on cell proliferation by upregulating p21 and downregulating TNF-α and IL-6 [70,71,72]. The authors demonstrated a significant reduction of p21 expression in liver tissues of ALF patients with spontaneous recovery and an induction of TNF-α and IL-6 in serum as compared to nonrecovered patients. These results suggested that miR-122 may accelerate LR through HO-1 inhibition in spontaneously recovered ALF patients. In addition, the authors further identified miR-122 as a biomarker in ALF patients with spontaneous recovery by an ROC curve analysis.

A20 promotes hepatocyte proliferation through a miR-203-dependent manner

A20, a zinc finger protein encoded by TNF-induced reaction genes, has been confirmed as a nuclear factor kappa B (NF-κB) inhibitor and a pro-proliferative factor in hepatocytes [73,74]. In Silva et al.'s study, IL-6-induced signal transducer and activator of transcription 3 (STAT3) signaling was enhanced in A20 overexpressing hepatocytes [43,44]. To further investigate the mechanism of A20 in accelerating LR, an animal model of A20 KO mice was established. The suppressor of cytokine signaling 3 (SOCS3) was found to be significantly increased in A20 KO livers, leading to subsequent inhibition of IL-6/STAT3 signaling. More importantly, SOCS3 was epigenetically regulated by miR-203 in hepatocytes [75,76,77]. As the upstream of SOCS3, miR-203 was significantly decreased in A20 KO mice. Taken together, these data suggest that A20 activates IL-6/STAT3 signaling and promotes hepatocyte proliferation via downregulating SOCS3 in a miR-203-dependent manner.

MiR-221 promotes hepatocyte proliferation via inhibiting Arnt

MiR-221 has been found to be upregulated in hepatocellular carcinoma (HCC) [78,79,80]. Meanwhile, it could delay fulminant liver failure and inhibit apoptosis of hepatocytes in mice, which implicates the potential promotive role of miR-221 in LR [81]. A recent study by Yuan et al. demonstrated higher numbers of BrdU- and Ki67-positive nuclei in cultivated primary hepatocytes transfected with miR-221 mimics compared with control cells, indicative of the promotive effect of miR-221 in hepatocyte proliferation in vitro [45]. To further determine if miR-221 could enhance hepatocyte proliferation in vivo, adeno-associated virus type 8 (AAV8-Ttr-miR-221) was used to overexpress miR-221 in the mouse liver followed by 70% PH to induce hepatocyte proliferation in vivo. Immunohistochemical analysis showed higher numbers of Ki67, BrdU, and PCNA-positive nuclei in miR-221 overexpressing mice than the controls at the peak of DNA synthesis (36 hr after PH), indicating a rapid entry into S phase of the cell division cycle in miR-221 overexpressing hepatocytes. Furthermore, a class of important cyclins, including cyclin D1, E1, A2, and B1, were found to be upregulated at 36 and 72 hrs after PH in livers of mice overexpressing miR-221. In addition, in silico analyses and luciferase reporter assay identified aryl hydrocarbon receptor nuclear translocator (Arnt) as a novel target gene of miR-221. Yuan et al. demonstrated that miR-221 mimics could decrease the expression of Arnt both at the mRNA and protein levels in hepatocytes. Luciferase assays further confirmed Arnt as a target gene of miR-221. Taken together, loss of Arnt contributes to the miR-221-induced hepatocyte proliferation [45]. However, it is worth mentioning that in John et al.'s study, ALF patients with spontaneous recovery (SR) showed higher serum levels of miR-21, miR-122 and miR-221, but significantly lower levels of miR-21 and miR-221 in liver biopsies, compared to nonrecovered patients [42]. Unlike this reciprocal expression pattern of miR-21 and miR-221, miR-122 was elevated in serum and liver tissue of SR patients. This suggests that the pro-proliferation effects of a given microRNA may not completely overlap the function of that miR in the regenerated tissue.

MiR-26a inhibits hepatocyte proliferation by repressing cyclin expression

Several studies have shown that miR-26a family members could suppress tumorigenesis in liver cancer cells and B lymphoma cells, and expression of miR-26a was also found to be significantly declined after 70% PH [39]. Adenovirusin 5 (Ad5)-anti-miR-26a-LUC was utilized to downregulate miR-26a in the mouse liver which resulted in enhanced proliferation of hepatocytes and improved liver function characterized by reduced serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin (T-Bil) during PH. Overexpression of miR-26a via Ad5-miR26a-LUC had inverse effects. These data showed an inhibitory effect of miR-26a on hepatocyte proliferation during LR. Cyclin D2 and cyclin E2 were identified as putative target genes of miR-26a using qRT-PCRs and Western blotting analysis. Thus, miR-26a is supposed to inhibit hepatocyte proliferation during LR via decreasing cyclin D2 and cyclin E2.

MiR-33 inhibits cell proliferation during LR

MiR-33 is considered as a key transcriptional factor in cholesterol biosynthesis and transport [82,83]. Meanwhile, as an intronic miRNA located within the gene encoding sterol-regulatory element-binding protein-2 (Srebp-2), miR-33 has been implicated in the regulation of cell cycle [84,85,86]. In Iwakiri et al.'s study, they found that miR-33 overexpression could inhibit CDK6 and cyclin D1 at mRNA level in A549 and Huh7 cell lines, which would lead to G1 cell cycle arrest and reduce cell proliferation [40]. Moreover, hepatic miR-33 level was found to be downregulated in the mouse liver at 24 hr after PH. Mice with anti-miR-33 treatment displayed enhanced hepatocyte proliferation and LR, paralleling with increased expressions of CDK6 and cyclin D1. Moreover, luciferase reporter assays confirmed that miR-33 directly targets the 3'-UTR of CDK6 and cyclin D1. Thus miR-33 reduces cell proliferation and cell cycle progression during LR via suppressing CDK6 and cyclin D1.

MiR-34a suppresses hepatocyte proliferation in the termination stage of LR

In Chen et al.'s study, a highly induction of miR-34a has been detected in livers of rats at 5 days after PH [41]. MTT assays and cell cycle analysis showed that the cell growth was significantly suppressed by overexpression of miR-34a in normal rat liver BRL-3A cells. As the correlation between LR termination and activin-A has been confirmed, the authors sought to verify the association between miR-34a and activin-A in termination regenerating livers. Activin-A, homodimer of two inhibin βB (INHBB) proteins, has been confirmed as an essential regulator to decelerate hepatocyte proliferation during the termination stage of LR [87,88]. Using luciferase reporter assay, INHBB has been identified as a direct target of miR-34a. BRL-3A cell proliferation was strongly repressed in INHBB siRNA group, indicating that INHBB downregulation represses hepatocyte proliferation. Moreover, as Met is a previously validated target gene of miR-34a [89,90,91,92] and has been proved to be essential for promoting hepatocyte proliferation during LR [93], the authors further demonstrated that miR-34a could downregulate Met at mRNA and protein levels in both BRL-3A cells and regenerating liver tissues following PH [93]. In summary, miR-34a was strongly induced during the termination stage of LR. Up-regulation of miR-34a could suppress hepatocyte proliferation through its inhibitory effects on INHBB and Met. Besides Met, several other regulators for cell cycle, including NMYC, cyclin D1, cyclin E2, CDK4, and CDK6, have previously been validated as potential target genes of miR-34a [94,95], though the downstream mechanisms mediating the inhibitory effect of miR-34a on hepatocyte proliferation during LR remain to be further elucidated.

MiR-127 suppresses hepatocyte proliferation through Bcl6 and Setd8 inhibition

MiR-127 is a small non-coding RNA characterized by its overlapping gene structure and functions of regulating gene expressions involved in cell apoptosis [96]. Aberrant expressions of miR-127 have been implicated in suppressing the growth of several types of cancers [97,98,99]. A recent study by Pan et al. demonstrated that the miR-127 level was downregulated in the rat liver at 24 hr after PH [36]. Overexpression of miR-127 in BRL-3A rat immortalized hepatocytes reduced cell growth and caused cell cycle arrest in the G2/M phase. By using bioinformatics analysis including TargetScan, miRanda and Pictar algorithms, B-cell lymphoma 6 protein (Bcl6) and SET domain-containing protein 8 (Setd8) were identified as two candidate target genes of miR-127. Bcl6 contributes to cell activation, differentiation and proliferation and has been verified as a transcriptional repressor for p53, ATR, and CDKN1A. Setd8, a member of the SET domain-containing methyltransferase family, plays a role in cell cycle regulation via targeting histone H4 lysine K20 (H4K20) for monomethylation [100]. Using qRT-PCR and Western blotting analysis, they found that the mRNA and protein levels of Bcl6 and Setd8 were remarkably increased in the rat liver at 24 hr after PH. Meanwhile, Bcl6 and Setd8 were downregulated at both mRNA and protein levels in rat hepatocytes treated with miR-127 mimics. Furthermore, Bcl6 si-RNA markedly reduced BRL-3A cell proliferation invitro. Taken together, these results suggest that downregulation of miR-127 could promote hepatocyte proliferation through increasing Bcl6 and Setd8 during LR.

Inhibition of miR-150 induces hepatocyte proliferation

Vascular endothelial growth factor (VEGF), an angiogenesis-inducing factor, has been confirmed as a promoter for the proliferation of sinusoidal endothelial cells and hepatocytes during LR [101,102,103]. Thus, miRNAs targeting VEGF have the possibility of regulating hepatocyte proliferation. To elucidate the potential association between VEGF and certain miRNAs during LR, Yu et al. carried out in silico analysis to determine the putative miRNAs targeting VEGF-A [37]. Seven of the putative miRNAs were selected by bioinformatics algorithms for further screening. Based on the results from qRT-PCRs, miR-150 was found to be significantly downregulated at the early stage of LR and was considered to possess the closest correlation to the VEGF-A gene. As VEGF-A was remarkably increased in liver tissues during LR, this alteration may be due to the inverse correlation between miR-150 and VEGF-A. To further confirm this hypothesis, cultivated primary hepatocytes were transfected with miR-150 inhibitors and both mRNA and protein levels of VEGF-A in hepatocytes were increased. In addition, an increased protein level of hypoxia-inducible factor-1α (HIF-1α) was detected in liver tissues at 24 hr and 48 hr post PH. Hypoxia-induced hepatocytes displayed decreased expression of miR-150 and upregulation of VEGF-A, suggesting that the low-level expression of miR-150 in the early phase of LR is associated with induction of HIF-1α.

Downregulation of miR-150, miR-663 and miR-503 were also reported in liver biopsies of patients who had undergone auxiliary liver transplantation [104]. Moreover, inhibition of miRNA-150, miRNA-503 and miRNA-663 promoted hepatocyte proliferation in vitro.

MiR-378 suppresses LR by inhibiting ornithine decarboxylase (Odc1)

In Song et al.'s study, miR-378 expression was decreased in liver tissues following 70% PH, indicating the inverse correlation with LR [38]. Ornithine decarboxylase (Odc1), which encodes a polyamine-synthesizing enzyme needed for DNA synthesis [105], has been reported to have a pro-proliferation effect. Using luciferase reporter assays, Odc1 was confirmed as a direct target gene of miR-378. These data revealed that downregulation of miR-378 contributes to LR via activating Odc1.

In this review, we summarized the current knowledge about differentially expressed miRNAs and their implications in the process of LR. The dynamic changes of miRNAs during liver regeneration include three types. MiR-16, miR-22, miR-23, miR-24, miR-26a, miR-29, miR-30, miR-31, miR-33, miR-122a, miR-126, miR-127, miR-145, miR-150 and miR-378 were downregulated during the process of LR. MiR-21, miR-26b, miR-192 and miR-194, were upregulated in the first day and then downregulated in the following two days. MiR-34a, miR-122, miR-203 and miR-221, were upregulated during the process of LR. Among the abnormally expressed miRNAs, miR-21, miR-23b, miR-122, miR-203 and miR-221 are verified as promoters for LR, while miR-26a, miR-33, miR-34a, miR-127, miR-150 and miR-378 have inverse effect (Fig. 1, 2). MiR-21, the most widely studied miRNA in LR, plays a positive role on hepatocyte proliferation through three different target genes, including suppressing Btg2, Rhob and PTEN. MiR-23b, which is notably reduced at the termination stage of LR, promotes hepatocyte proliferation through the TGF-β1/miR-23b/smad3 signaling pathway. MiR-122 is identified as a biomarker with a high sensitivity of ALF patients with spontaneous recovery, and no direct evidence has been shown in its roles in LR. MiR-203, induced by A20, may lead to hepatocyte proliferation by activating IL-6/STAT3 signaling. MiR-221 has a promotive effect on LR by activating cyclin D1, E1, A2 and B1, and inhibiting Arnt. MiR-26a is supposed to inhibit hepatocyte proliferation during LR via suppressing cyclin D2 and cyclin E2. MiR-33 reduces cell proliferation and cell cycle progression during LR via inhibiting CDK6 and cyclin D1. MiR-34a suppresses hepatocyte proliferation in the termination stage of LR through an inhibitory effect on INHBB and Met. MiR-127 reduces hepatocytes growth and causes cell cycle arrest in the G2/M phase through Bcl6 and Setd8 inhibition. Downregulation of miRNA-150, miRNA-503 and miRNA-663 promote hepatocyte proliferation in vitro. MiR-378 suppresses LR by inhibiting Odc1. Despite of a growing number of studies on miRNAs in the regulation of hepatocyte proliferation and LR, molecular and functional mechanisms of how miRNA dysregulation impacts LR are not completely understood.

This review focused on hepatocyte proliferation during the process of LR, under the hypothesis of the unimpaired hepatocyte proliferation. However, it's worth mentioning that several cell types can contribute to regeneration following toxin-mediated damage, such as oval/progenitor cells though the role of stem cells in LR is under debate [106]. The oval cells, named for their appearance, are associated with ductular reaction, a regenerative process occurs in LR [107,108]. In addition, they express biliary epithelial cells (BECs)-markers, hepatocyte-specific markers and the embryonic liver marker α-fetoprotein. Kordes et al. identified the mesenchymal hepatic stellate cells (HSCs) as potential sources of oval cells for the regenerating liver [109]. They transplanted HSCs into rats with liver injury and determined these cells as a liver stem cell pool in the regenerating liver. However, the source of oval/progenitor cells remains unknown.

Two strategies could be proposed for enhancing LR by targeting miRNA. For those miRNAs enhancing LR, miRNA mimics could be used to enhance LR. A case in point is the first phase I study of miR-24 mimics used in liver cancer. The nature of miRNA mimics are double-stranded RNAs used to mimic endogenous miRNAs. For those miRNAs attenuating LR, miRNA antagomirs could be used to enhance LR. A case in point is the phase II trial of miR-122 antagomir used in hepatitis. Antagomirs are chemically engineered oligonucleotides which used to silence endogenous miRNAs [110].

In conclusion, better understanding of the roles of miRNAs in LR will definitely help enhance the understanding of the regenerative process and open up a new prospect for liver transplantation.

This work was supported by the grants from National Natural Science Foundation of China (81200169 to J. Xiao; 81400647 to Y. Bei; 81070343 and 81370559 to C. Yang; 81400635 to F. Wang), Innovation Program of Shanghai Municipal Education Commission (13YZ014 to J. Xiao), Foundation for University Young Teachers by Shanghai Municipal Education Commission (year 2012, to J. Xiao), Innovation fund from Shanghai University (sdcx2012038 to J. Xiao), and Program for the integration of production, teaching and research for University Teachers supported by Shanghai Municipal Education Commission (year 2014, to J. Xiao), Shanghai Medical Guide Project from Shanghai Science and Technology Committee (14411971500 to F. Wang), and China Postdoctoral Science Foundation (2014M561456 to Y. Bei), Jonit Projects in Major Diseases funding from Shanghai Municipal Commission of Health and Family Planning (2014ZYJB0201 to C. Yang), Jonit Projects for Novel Fronrier Technology in Shanghai Municipal Hospital from Shanghai Municipal Commission of Health and Family Planning (SHDC1204122 to C. Yang), Shanghai Medical Guide Project from Shanghai Science and Technology Committee (14411971500 to F. Wang), grants from Chinese Foundation for Hepatitis Prevention and Control (TQGB20140141 to F. Wang) and funds from Shanghai Innovation Program (12431901002 to C. Yang).

The authors declare there are no conflicts of interest.

1.
Laurence J: Centennial celebration of translational research: The journal of laboratory and clinical medicine. Transl Res 2015;165:1-6.
2.
Zimmermann A: Liver regeneration: The emergence of new pathways. Med Sci Monit 2002;8:RA53-63.
3.
Fausto N: Liver regeneration. J Hepatol 2000;32:19-31.
4.
Michalopoulos GK, DeFrances M: Liver regeneration. Adv Biochem Eng Biotechnol 2005;93:101-134.
5.
Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, DeMatteo RP, D'Angelica M, Blumgart LH, Jarnagin WR: Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003;7:1034-1044.
6.
Gilgenkrantz H, Collin de l'Hortet A: New insights into liver regeneration. Clin Res Hepatol Gastroenterol 2011;35:623-629.
7.
Jia C: Advances in the regulation of liver regeneration. Expert Rev Gastroenterol Hepatol 2011;5:105-121.
8.
Albrecht JH, Hansen LK: Cyclin d1 promotes mitogen-independent cell cycle progression in hepatocytes. Cell Growth Differ 1999;10:397-404.
9.
Ueda J, Chijiiwa K, Nakano K: Cyclin expression in the atrophying and proliferating lobes of the liver after portal vein branch ligation and hepatectomy in rats. J Surg Res 2004;120:89-96.
10.
Borowiak M, Garratt AN, Wustefeld T, Strehle M, Trautwein C, Birchmeier C: Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A 2004;101:10608-10613.
11.
Fausto N, Laird AD, Webber EM: Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995;9:1527-1536.
12.
Akerman P, Cote P, Yang SQ, McClain C, Nelson S, Bagby GJ, Diehl AM: Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol 1992;263:G579-585.
13.
Blindenbacher A, Wang X, Langer I, Savino R, Terracciano L, Heim MH: Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology 2003;38:674-682.
14.
Court FG, Wemyss-Holden SA, Dennison AR, Maddern GJ: The mystery of liver regeneration. Br J Surg 2002;89:1089-1095.
15.
Menthena A, Koehler CI, Sandhu JS, Yovchev MI, Hurston E, Shafritz DA, Oertel M: Activin a, p15ink4b signaling, and cell competition promote stem/progenitor cell repopulation of livers in aging rats. Gastroenterology 2011;140:1009-1020.
16.
Endo D, Maku-Uchi M, Kojima I: Activin or follistatin: Which is more beneficial to support liver regeneration after massive hepatectomy? Endocr J 2006;53:73-78.
17.
Oe S, Lemmer ER, Conner EA, Factor VM, Leveen P, Larsson J, Karlsson S, Thorgeirsson SS: Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice. Hepatology 2004;40:1098-1105.
18.
Lau AL, Kumar TR, Nishimori K, Bonadio J, Matzuk MM: Activin betac and betae genes are not essential for mouse liver growth, differentiation, and regeneration. Mol Cell Biol 2000;20:6127-6137.
19.
Machado MV, Diehl AM: Liver renewal: Detecting misrepair and optimizing regeneration. Mayo Clin Proc 2014;89:120-130.
20.
Nygard IE, Mortensen KE, Hedegaard J, Conley LN, Kalstad T, Bendixen C, Revhaug A: The genetic regulation of the terminating phase of liver regeneration. Comp Hepatol 2012;11:3.
21.
Liska V, Treska V, Mirka H, Kobr J, Sykora R, Skalicky T, Sutnar A, Vycital O, Bruha J, Pitule P, Chlumska A, Racek J, Benes J, Holubec L: Inhibition of transforming growth factor beta-1 augments liver regeneration after partial portal vein ligation in a porcine experimental model. Hepatogastroenterology 2012;59:235-240.
22.
Gehrau RC, Mas VR, Maluf DG: Hepatic disease biomarkers and liver transplantation: What is the potential utility of micrornas? Expert Rev Gastroenterol Hepatol 2013;7:157-170.
23.
Carthew RW, Sontheimer EJ: Origins and mechanisms of mirnas and sirnas. Cell 2009;136:642-655.
24.
Kim VN, Han J, Siomi MC: Biogenesis of small rnas in animals. Nat Rev Mol Cell Biol 2009;10:126-139.
25.
Sayed D, Abdellatif M: Micrornas in development and disease. Physiol Rev 2011;91:827-887.
26.
Feng YY, Xu XQ, Ji CB, Shi CM, Guo XR, Fu JF: Aberrant hepatic microrna expression in nonalcoholic fatty liver disease. Cell Physiol Biochem 2014;34:1983-1997.
27.
Chen L, Li YS, Cui J, Ning JN, Wang GS, Qian GS, Lu KZ, Yi B: Mir-206 controls the phenotypic modulation of pulmonary arterial smooth muscle cells induced by serum from rats with hepatopulmonary syndrome by regulating the target gene, annexin a2. Cell Physiol Biochem 2014;34:1768-1779.
28.
Jia HY, Chen F, Chen JZ, Wu SS, Wang J, Cao QY, Chen Z, Zhu HH: Microrna expression profiles related to early stage murine concanavalin a-induced hepatitis. Cell Physiol Biochem 2014;33:1933-1944.
29.
Zhou J, Lu S, Yang S, Chen H, Shi H, Miao M, Jiao B: Microrna-127 post-transcriptionally downregulates sept7 and suppresses cell growth in hepatocellular carcinoma cells. Cell Physiol Biochem 2014;33:1537-1546.
30.
Guo J, Li M, Meng X, Sui J, Dou L, Tang W, Huang X, Man Y, Wang S, Li J: Mir-291b-3p induces apoptosis in liver cell line nctc1469 by reducing the level of rna-binding protein hur. Cell Physiol Biochem 2014;33:810-822.
31.
Qiu YH, Wei YP, Shen NJ, Wang ZC, Kan T, Yu WL, Yi B, Zhang YJ: Mir-204 inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells. Cell Physiol Biochem 2013;32:1331-1341.
32.
Li H, Li Y, Liu D, Sun H, Liu J: Mir-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells. Cell Physiol Biochem 2013;32:448-458.
33.
Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V: Challenges in using circulating mirnas as cancer biomarkers. Biomed Res Int 2015;2015:731479.
34.
Roy S, Benz F, Luedde T, Roderburg C: The role of mirnas in the regulation of inflammatory processes during hepatofibrogenesis. Hepatobiliary Surg Nutr 2015;4:24-33.
35.
Chen X, Murad M, Cui YY, Yao LJ, Venugopal SK, Dawson K, Wu J: Mirna regulation of liver growth after 50% partial hepatectomy and small size grafts in rats. Transplantation 2011;91:293-299.
36.
Pan C, Chen H, Wang L, Yang S, Fu H, Zheng Y, Miao M, Jiao B: Down-regulation of mir-127 facilitates hepatocyte proliferation during rat liver regeneration. PloS one 2012;7:e39151.
37.
Yu ZY, Bai YN, Luo LX, Wu H, Zeng Y: Expression of microrna-150 targeting vascular endothelial growth factor-a is downregulated under hypoxia during liver regeneration. Mol Med Rep 2013;8:287-293.
38.
Song G, Sharma AD, Roll GR, Ng R, Lee AY, Blelloch RH, Frandsen NM, Willenbring H: Micrornas control hepatocyte proliferation during liver regeneration. Hepatology 2010;51:1735-1743.
39.
Zhou J, Ju W, Wang D, Wu L, Zhu X, Guo Z, He X: Down-regulation of microrna-26a promotes mouse hepatocyte proliferation during liver regeneration. PloS one 2012;7:e33577.
40.
Iwakiri Y: A role of mir-33 for cell cycle progression and cell proliferation. Cell Cycle 2012;11:1057-1058.
41.
Chen H, Sun Y, Dong R, Yang S, Pan C, Xiang D, Miao M, Jiao B: Mir-34a is upregulated during liver regeneration in rats and is associated with the suppression of hepatocyte proliferation. PloS one 2011;6:e20238.
42.
John K, Hadem J, Krech T, Wahl K, Manns MP, Dooley S, Batkai S, Thum T, Schulze-Osthoff K, Bantel H: Micrornas play a role in spontaneous recovery from acute liver failure. Hepatology 2014;60:1346-1355.
43.
da Silva CG, Studer P, Skroch M, Mahiou J, Minussi DC, Peterson CR, Wilson SW, Patel VI, Ma A, Csizmadia E, Ferran C: A20 promotes liver regeneration by decreasing socs3 expression to enhance il-6/stat3 proliferative signals. Hepatology 2013;57:2014-2025.
44.
da Silva CG, Cervantes JR, Studer P, Ferran C: A20-an omnipotent protein in the liver: Prometheus myth resolved? Adv Exp Med Biol 2014;809:117-139.
45.
Yuan Q, Loya K, Rani B, Mobus S, Balakrishnan A, Lamle J, Cathomen T, Vogel A, Manns MP, Ott M, Cantz T, Sharma AD: Microrna-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology 2013;57:299-310.
46.
Dippold RP, Vadigepalli R, Gonye GE, Hoek JB: Chronic ethanol feeding enhances mir-21 induction during liver regeneration while inhibiting proliferation in rats. Am J Physiol Gastrointest Liver Physiol 2012;303:G733-743.
47.
Dippold RP, Vadigepalli R, Gonye GE, Patra B, Hoek JB: Chronic ethanol feeding alters mirna expression dynamics during liver regeneration. Alcohol Clin Exp Res 2013;37:E59-69.
48.
Fukuhara Y, Hirasawa A, Li XK, Kawasaki M, Fujino M, Funeshima N, Katsuma S, Shiojima S, Yamada M, Okuyama T, Suzuki S, Tsujimoto G: Gene expression profile in the regenerating rat liver after partial hepatectomy. J Hepatol 2003;38:784-792.
49.
Dransfeld O, Gehrmann T, Kohrer K, Kircheis G, Holneicher C, Haussinger D, Wettstein M: Oligonucleotide microarray analysis of differential transporter regulation in the regenerating rat liver. Liver Int 2005;25:1243-1258.
50.
Ho CM, Lee PH, Lai YT, Hu RH, Ho MC, Wu YM: Gene expression profiles in living donors immediately after partial hepatectomy - the initial response of liver regeneration. J Formos Med Assoc 2007;106:288-294.
51.
Hanse EA, Nelsen CJ, Goggin MM, Anttila CK, Mullany LK, Berthet C, Kaldis P, Crary GS, Kuriyama R, Albrecht JH: Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin d1 expression in vivo. Cell cycle 2009;8:2802-2809.
52.
Shu J, Kren BT, Xia Z, Wong PY, Li L, Hanse EA, Min MX, Li B, Albrecht JH, Zeng Y, Subramanian S, Steer CJ: Genomewide microrna down-regulation as a negative feedback mechanism in the early phases of liver regeneration. Hepatology 2011;54:609-619.
53.
Li S, Zhu J, Fu H, Wan J, Hu Z, Liu S, Li J, Tie Y, Xing R, Zhu J, Sun Z, Zheng X: Hepato-specific microrna-122 facilitates accumulation of newly synthesized mirna through regulating prkra. Nucleic Acids Res 2012;40:884-891.
54.
Sekine S, Ogawa R, Ito R, Hiraoka N, McManus MT, Kanai Y, Hebrok M: Disruption of dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 2009;136:2304-2315.
55.
Kren BT, Wong PY, Shiota A, Zhang X, Zeng Y, Steer CJ: Polysome trafficking of transcripts and micrornas in regenerating liver after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol 2009;297:G1181-1192.
56.
Maroney PA, Yu Y, Fisher J, Nilsen TW: Evidence that micrornas are associated with translating messenger rnas in human cells. Nat Struct Mol Biol 2006;13:1102-1107.
57.
Veyrune JL, Hesketh J, Blanchard JM: 3' untranslated regions of c-myc and c-fos mrnas: Multifunctional elements regulating mrna translation, degradation and subcellular localization. Prog Mol Subcell Biol 1997;18:35-63.
58.
Yang Q, Xu E, Dai J, Wu J, Zhang S, Peng B, Jiang Y: Mir-21 regulates n-methyl-n-nitro-n'-nitrosoguanidine-induced gastric tumorigenesis by targeting faslg and btg2. Toxicol Lett 2014;228:147-156.
59.
Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gulla A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P: Targeting mir-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013;19:2096-2106.
60.
Liu M, Wu H, Liu T, Li Y, Wang F, Wan H, Li X, Tang H: Regulation of the cell cycle gene, btg2, by mir-21 in human laryngeal carcinoma. Cell Res 2009;19:828-837.
61.
Ng R, Song G, Roll GR, Frandsen NM, Willenbring H: A microrna-21 surge facilitates rapid cyclin d1 translation and cell cycle progression in mouse liver regeneration. J Clin Invest 2012;122:1097-1108.
62.
Yan-nan B, Zhao-yan Y, Li-xi L, jiang Y, Qing-jie X, Yong Z: Microrna-21 accelerates hepatocyte proliferation in vitro via pi3k/akt signaling by targeting pten. Biochem Biophys Res Commun 2014;443:802-807.
63.
Castro RE, Ferreira DM, Zhang X, Borralho PM, Sarver AL, Zeng Y, Steer CJ, Kren BT, Rodrigues CM: Identification of micrornas during rat liver regeneration after partial hepatectomy and modulation by ursodeoxycholic acid. Am J Physiol Gastrointest Liver Physiol 2010;299:G887-897.
64.
Rogler CE, Levoci L, Ader T, Massimi A, Tchaikovskaya T, Norel R, Rogler LE: Microrna-23b cluster micrornas regulate transforming growth factor-beta/bone morphogenetic protein signaling and liver stem cell differentiation by targeting smads. Hepatology 2009;50:575-584.
65.
Do N, Zhao R, Ray K, Ho K, Dib M, Ren X, Kuzontkoski P, Terwilliger E, Karp SJ: Bmp4 is a novel paracrine inhibitor of liver regeneration. Am J Physiol Gastrointest Liver Physiol 2012;303:G1220-1227.
66.
Sosa I, Cvijanovic O, Celic T, Cuculic D, Crncevic-Orlic Z, Vukelic L, Zoricic Cvek S, Dudaric L, Bosnar A, Bobinac D: Hepatoregenerative role of bone morphogenetic protein-9. Med Sci Monit 2011;17:HY33-35.
67.
Yuan B, Dong R, Shi D, Zhou Y, Zhao Y, Miao M, Jiao B: Down-regulation of mir-23b may contribute to activation of the tgf-beta1/smad3 signalling pathway during the termination stage of liver regeneration. FEBS Lett 2011;585:927-934.
68.
Best J, Dolle L, Manka P, Coombes J, van Grunsven LA, Syn WK: Role of liver progenitors in acute liver injury. Front Physiol 2013;4:258.
69.
Michalopoulos GK: Liver regeneration after partial hepatectomy: Critical analysis of mechanistic dilemmas. Am J Pathol 2010;176:2-13.
70.
Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, Clinton Webb R, Lee ME, Nabel GJ, Nabel EG: Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 2001;7:693-698.
71.
Schwer CI, Mutschler M, Stoll P, Goebel U, Humar M, Hoetzel A, Schmidt R: Carbon monoxide releasing molecule-2 inhibits pancreatic stellate cell proliferation by activating p38 mitogen-activated protein kinase/heme oxygenase-1 signaling. Mol Pharmacol 2010;77:660-669.
72.
Qiu L, Fan H, Jin W, Zhao B, Wang Y, Ju Y, Chen L, Chen Y, Duan Z, Meng S: Mir-122-induced down-regulation of ho-1 negatively affects mir-122-mediated suppression of hbv. Biochem Biophys Res Commun 2010;398:771-777.
73.
Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM: De-ubiquitination and ubiquitin ligase domains of a20 downregulate nf-kappab signalling. Nature 2004;430:694-699.
74.
Longo CR, Patel VI, Shrikhande GV, Scali ST, Csizmadia E, Daniel S, Sun DW, Grey ST, Arvelo MB, Ferran C: A20 protects mice from lethal radical hepatectomy by promoting hepatocyte proliferation via a p21waf1-dependent mechanism. Hepatology 2005;42:156-164.
75.
Zhou X, Liu W, Gu M, Zhou H, Zhang G: Helicobacter pylori infection causes hepatic insulin resistance by the c-jun/mir-203/socs3 signaling pathway. J Gastroenterol DOI:10.1007/s00535-015-1051-6.
76.
Chu F, Barkinge J, Hawkins S, Gudi R, Salgia R, Kanteti PV: Expression of siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: Effect of elevated levels of bcl-2. Cancer Res 2005;65:5301-5309.
77.
Moffatt CE, Lamont RJ: Porphyromonas gingivalis induction of microrna-203 expression controls suppressor of cytokine signaling 3 in gingival epithelial cells. Infect Immun 2011;79:2632-2637.
78.
Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD: Association of microrna expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008;14:419-427.
79.
Yoon SO, Chun SM, Han EH, Choi J, Jang SJ, Koh SA, Hwang S, Yu E: Deregulated expression of microrna-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. Hum Pathol 2011;42:1391-1400.
80.
Li J, Wang Y, Yu W, Chen J, Luo J: Expression of serum mir-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011;406:70-73.
81.
Sharma AD, Narain N, Handel EM, Iken M, Singhal N, Cathomen T, Manns MP, Scholer HR, Ott M, Cantz T: Microrna-221 regulates fas-induced fulminant liver failure. Hepatology 2011;53:1651-1661.
82.
Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernandez-Hernando C: Mir-33 contributes to the regulation of cholesterol homeostasis. Science 2010;328:1570-1573.
83.
Goedeke L, Salerno A, Ramirez CM, Guo L, Allen RM, Yin X, Langley SR, Esau C, Wanschel A, Fisher EA, Suarez Y, Baldan A, Mayr M, Fernandez-Hernando C: Long-term therapeutic silencing of mir-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol Med 2014;6:1133-1141.
84.
Goedeke L, Vales-Lara FM, Fenstermaker M, Cirera-Salinas D, Chamorro-Jorganes A, Ramirez CM, Mattison JA, de Cabo R, Suarez Y, Fernandez-Hernando C: A regulatory role for microrna 33* in controlling lipid metabolism gene expression. Mol Cell Biol 2013;33:2339-2352.
85.
Shao F, Wang X, Yu J, Jiang H, Zhu B, Gu Z: Expression of mir-33 from an srebf2 intron targets the fto gene in the chicken. PloS one 2014;9:e91236.
86.
Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, Usami S, Izuhara M, Sowa N, Yahagi N, Shimano H, Matsumura S, Inoue K, Marusawa H, Nakamura T, Hasegawa K, Kume N, Yokode M, Kita T, Kimura T, Ono K: Microrna-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nature Commun 2013;4:2883.
87.
Huang X, Li D, Lu H, Wang Z, Wei H, Wang Y, Zhang J, Xu Q: [Expression of activins, follistatin mrna in the development of hepatic fibrosis]. Zhonghua Gan Zang Bing Za Zhi 2002;10:85-88.
88.
Li L, Shen JJ, Bournat JC, Huang L, Chattopadhyay A, Li Z, Shaw C, Graham BH, Brown CW: Activin signaling: Effects on body composition and mitochondrial energy metabolism. Endocrinology 2009;150:3521-3529.
89.
Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X: Mir-34a inhibits migration and invasion by down-regulation of c-met expression in human hepatocellular carcinoma cells. Cancer Lett 2009;275:44-53.
90.
He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ: A microrna component of the p53 tumour suppressor network. Nature 2007;447:1130-1134.
91.
Peng Y, Guo JJ, Liu YM, Wu XL: Microrna-34a inhibits the growth, invasion and metastasis of gastric cancer by targeting pdgfr and met expression. Biosci Rep DOI: 10.1042/BSR20140020.
92.
Zhou JY, Chen X, Zhao J, Bao Z, Chen X, Zhang P, Liu ZF, Zhou JY: Microrna-34a overcomes hgf-mediated gefitinib resistance in egfr mutant lung cancer cells partly by targeting met. Cancer Lett 2014;351:265-271.
93.
Apte U, Gkretsi V, Bowen WC, Mars WM, Luo JH, Donthamsetty S, Orr A, Monga SP, Wu C, Michalopoulos GK: Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology 2009;50:844-851.
94.
Chen F, Hu SJ: Effect of microrna-34a in cell cycle, differentiation, and apoptosis: A review. J Biochem Mol Toxicol 2012;26:79-86.
95.
Cirera-Salinas D, Pauta M, Allen RM, Salerno AG, Ramirez CM, Chamorro-Jorganes A, Wanschel AC, Lasuncion MA, Morales-Ruiz M, Suarez Y, Baldan A, Esplugues E, Fernandez-Hernando C: Mir-33 regulates cell proliferation and cell cycle progression. Cell cycle 2012;11:922-933.
96.
Song G, Wang L: Mir-433 and mir-127 arise from independent overlapping primary transcripts encoded by the mir-433-127 locus. PloS one 2008;3:e3574.
97.
Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA: Specific activation of microrna-127 with downregulation of the proto-oncogene bcl6 by chromatin-modifying drugs in human cancer cells. Cancer cell 2006;9:435-443.
98.
You W, Wang Y, Zheng J: Plasma mir-127 and mir-218 might serve as potential biomarkers for cervical cancer. Reprod Sci 2015;22:1037-1041.
99.
Wang S, Li H, Wang J, Wang D, Yao A, Li Q: Prognostic and biological significance of microrna-127 expression in human breast cancer. Dis Markers 2014;2014:401986.
100.
Yang F, Sun L, Li Q, Han X, Lei L, Zhang H, Shang Y: Set8 promotes epithelial-mesenchymal transition and confers twist dual transcriptional activities. EMBO J 2012;31:110-123.
101.
Bockhorn M, Goralski M, Prokofiev D, Dammann P, Grunewald P, Trippler M, Biglarnia A, Kamler M, Niehues EM, Frilling A, Broelsch CE, Schlaak JF: Vegf is important for early liver regeneration after partial hepatectomy. J Surg Res 2007;138:291-299.
102.
Taniguchi E, Sakisaka S, Matsuo K, Tanikawa K, Sata M: Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem 2001;49:121-130.
103.
Gu Y, Sowa JP, Paul A, Gerken G, Schlaak JF: Vascular endothelial growth factor improves liver regeneration and survival after 90% hepatectomy in a rat model of diet-induced steatosis. Digestion 2013;88:235-242.
104.
Salehi S, Brereton HC, Arno MJ, Darling D, Quaglia A, O'Grady J, Heaton N, Aluvihare VR: Human liver regeneration is characterized by the coordinated expression of distinct microrna governing cell cycle fate. Am J Transplant 2013;13:1282-1295.
105.
Karlsson A, Helou K, Walentinsson A, Hedrich HJ, Szpirer C, Levan G: Amplification of mycn, ddx1, rrm2, and odc1 in rat uterine endometrial carcinomas. Genes Chromosomes Cancer 2001;31:345-356.
106.
Hindley CJ, Mastrogiovanni G, Huch M: The plastic liver: Differentiated cells, stem cells, every cell? J Clin Invest 2014;124:5099-5102.
107.
Williams MJ, Clouston AD, Forbes SJ: Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology 2014;146:349-356.
108.
Farber E: Similarities in the sequence of early histological changes induced in the liver of the rat by ethionine, 2-acetylamino-fluorene, and 3'-methyl-4-dimethylaminoazobenzene. Cancer Res 1956;16:142-148.
109.
Kordes C, Sawitza I, Gotze S, Herebian D, Haussinger D: Hepatic stellate cells contribute to progenitor cells and liver regeneration. J Clin Invest 2014;124:5503-5515.
110.
Lv D, Liu J, Zhao C, Sun Q, Zhou Q, Xu J, Xiao J: Targeting micrornas in pathological hypertrophy and cardiac failure. Mini Rev Med Chem 2015;15:475-478.

X. Chen, Y. Zhao and F. Wang contributed equally to this work.

Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.